NCT04407819

Sarcopenia and Diabetes Mellitus

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: Dionyssiotis, Yannis, M.D. · Individual
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The association of diabetes mellitus type 2 (T2DM) with sarcopenia has not been adequately investigated. Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass which may affect performance.

Detailed description

The relationship between DM and sarcopenia has not been extensively investigated. Skeletal muscle is the primary site of glucose deposition, and decreased muscle mass plays a role in impaired glucose metabolism in patients with insulin resistance and type 2 diabetes. Skeletal muscle resistance to insulin action appears to be the link between type 2 diabetes (T2DM) and sarcopenia. Hyperglycemia is a metabolic dysfunction which can potentially damage muscle cells. Insulin deficiency leads to marked muscle catabolism that can be reversed by exogenous insulin administration. The metabolic disorder in diabetics may be reversible.Thus, it may be possible to restore physical ability by restoring the musculoskeletal system.Therefore, the diagnosis of sarcopenia if made can lead to interventions which may prevent the deterioration of body composition and the subsequent deterioration of quality of life. According to the results of the aforementioned studies it is still inconclusive if the metabolic disorder in diabetes may be related to sarcopenia, or sarcopenia may be a consequence of diabetes.

Conditions

• Sarcopenia

Interventions

Type	Name	Description
RADIATION	WHOLE BODY DXA	Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)

Timeline

• Start date: 2018-03-20
• Primary completion: 2018-07-31
• Completion: 2018-09-22
• First posted: 2020-05-29
• Last updated: 2020-05-29

Locations

1 site across 1 country: Greece